Literature DB >> 23768302

Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.

Leticia Alonso-Castro1, Luis Ríos-Buceta, Sergio Vano-Galvan, Carmen Moreno, Ainara Soria-Rivas, Pedro Jaén.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23768302     DOI： 10.1016/j.jaad.2013.01.012

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  3 in total

1.  Can Vemurafenib Induce Vitiligo in Metastatic Melanoma Patients?

Authors:  Ricardo Ruiz-Villaverde; Daniel Sánchez-Cano
Journal:  Balkan Med J       Date:  2016-01-01       Impact factor: 2.021

Review 2.  Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.

Authors:  Julia Dai; Viswanath R Belum; Shenhong Wu; Vincent Sibaud; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2017-09-14       Impact factor: 11.527

Review 3.  BRAF inhibitors: experience in thyroid cancer and general review of toxicity.

Authors:  M E Cabanillas; A Patel; B P Danysh; R Dadu; S Kopetz; G Falchook
Journal:  Horm Cancer       Date:  2014-12-03       Impact factor: 3.869
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.